{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:16:36Z","timestamp":1789038996963,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s11916-024-01295-7","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T14:02:20Z","timestamp":1720101740000},"page":"1135-1143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Frontiers in Acute Pain Management: Emerging Concepts in Pain Pathways and the Role of VX-548 as a Novel NaV1.8 Inhibitor: A Narrative Review"],"prefix":"10.1007","volume":"28","author":[{"given":"Alan D.","family":"Kaye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin S.","family":"Everett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna M.","family":"Lehuquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Maitski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Plessala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonnah","family":"Barrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Jean","family":"Baptiste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"George","family":"Mychaskiw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"issue":"1","key":"1295_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev-criminol-030421-040140","volume":"6","author":"M Gottschalk","year":"2023","unstructured":"Gottschalk M. The opioid crisis: The war on drugs is over. Long live the war on drugs. Ann Rev Criminol. 2023;6(1):363\u201398. https:\/\/doi.org\/10.1146\/annurev-criminol-030421-040140.","journal-title":"Ann Rev Criminol"},{"issue":"25","key":"1295_CR2","doi-asserted-by":"publisher","first-page":"eabm8147","DOI":"10.1126\/sciadv.abm8147","volume":"8","author":"EJ Stringfellow","year":"2022","unstructured":"Stringfellow EJ, Lim TY, Humphreys K, DiGennaro C, Stafford C, Beaulieu E, Homer J, Wakeland W, Bearnot B, McHugh RK, Kelly J, Glos L, Eggers SL, Kazemi R, Jalali MS. Reducing opioid use disorder and overdose deaths in the United States: A dynamic modeling analysis. Sci Adv. 2022;8(25):eabm8147. https:\/\/doi.org\/10.1126\/sciadv.abm8147.","journal-title":"Sci Adv"},{"issue":"4","key":"1295_CR3","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/j.pain.0000000000002423","volume":"163","author":"E Nury","year":"2022","unstructured":"Nury E, Schmucker C, Nagavci B, Motschall E, Nitschke K, Schulte E, Wegwarth O, Meerpohl JJ. Efficacy and safety of strong opioids for chronic noncancer pain and chronic low back pain: A systematic review and meta-analyses. Pain. 2022;163(4):610. https:\/\/doi.org\/10.1097\/j.pain.0000000000002423.","journal-title":"Pain"},{"issue":"3","key":"1295_CR4","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1097\/GOX.0000000000002125","volume":"7","author":"R Torabi","year":"2019","unstructured":"Torabi R, Bourn L, Mundinger GS, Saeg F, Patterson C, Gimenez A, Wisecarver I, St. Hilaire H, Stalder M, Tessler O. American society of plastic surgeons member post-operative opioid prescribing patterns. Plast Reconstruct Surg Glob Open. 2019;7(3):2125. https:\/\/doi.org\/10.1097\/GOX.0000000000002125.","journal-title":"Plast Reconstruct Surg Glob Open"},{"issue":"7","key":"1295_CR5","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/jamasurg.2017.0898","volume":"152","author":"EC Wick","year":"2017","unstructured":"Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: a review. JAMA Surg. 2017;152(7):691\u20137. https:\/\/doi.org\/10.1001\/jamasurg.2017.0898.","journal-title":"JAMA Surg"},{"issue":"10","key":"1295_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/j.1460-9592.2008.02764.x","volume":"18","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ. Paracetamol (Acetaminophen): Mechanisms of action. Paediatr Anaesth. 2008;18(10):915\u201321. https:\/\/doi.org\/10.1111\/j.1460-9592.2008.02764.x.","journal-title":"Paediatr Anaesth"},{"key":"1295_CR7","unstructured":"Ghlichloo I, Gerriets V. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). In StatPearls. StatPearls Publishing. 2023. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547742\/."},{"issue":"2","key":"1295_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/2049463720912496","volume":"14","author":"M Chincholkar","year":"2020","unstructured":"Chincholkar M. Gabapentinoids: Pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain. 2020;14(2):104\u201314. https:\/\/doi.org\/10.1177\/2049463720912496.","journal-title":"Br J Pain"},{"issue":"5","key":"1295_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1468-2982.2008.01800.x","volume":"29","author":"R Gil-Gouveia","year":"2009","unstructured":"Gil-Gouveia R, Goadsby P. Neuropsychiatric side-effects of lidocaine: Examples from the treatment of headache and a review. Cephalalgia. 2009;29(5):496\u2013508. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01800.x.","journal-title":"Cephalalgia"},{"key":"1295_CR10","doi-asserted-by":"publisher","unstructured":"Witty DR, MacPherson DT, Giblin GMP. 7.04\u2014Sodium Channel Blockers for the Treatment of Pain. In S. Chackalamannil, D. Rotella, & S. E. Ward (Eds.), Comprehensive Medicinal Chemistry III 2017:131\u2013175. Elsevier. https:\/\/doi.org\/10.1016\/B978-0-12-409547-2.12439-4.","DOI":"10.1016\/B978-0-12-409547-2.12439-4"},{"key":"1295_CR11","doi-asserted-by":"publisher","first-page":"174480691985880","DOI":"10.1177\/1744806919858801","volume":"15","author":"S Hameed","year":"2019","unstructured":"Hameed S. Nav1.7 and Nav1.8: Role in the pathophysiology of pain. Mol Pain. 2019;15:1744806919858801. https:\/\/doi.org\/10.1177\/1744806919858801.","journal-title":"Mol Pain"},{"issue":"8","key":"1295_CR12","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1097\/j.pain.0000000000001227","volume":"159","author":"A McDonnell","year":"2018","unstructured":"McDonnell A, Collins S, Ali Z, Iavarone L, Surujbally R, Kirby S, Butt RP. Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy. PAIN. 2018;159(8):1465. https:\/\/doi.org\/10.1097\/j.pain.0000000000001227.","journal-title":"PAIN"},{"issue":"14","key":"1295_CR13","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1111\/bph.15327","volume":"179","author":"DA Eagles","year":"2022","unstructured":"Eagles DA, Chow CY, King GF. Fifteen years of NaV1.7 channels as an analgesic target: Why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy? Br J Pharmacol. 2022;179(14):3592\u2013611. https:\/\/doi.org\/10.1111\/bph.15327. This paper delves into the history of why NaV1.7 inhibitors have been targeted for pharmacological development to inhibit pain, as well as possible reasons why this has not yet played out as well as envisioned yet and what properties an effective NaV1.7 inhibitor may have that previous trial inhibitors did not.","journal-title":"Br J Pharmacol"},{"key":"1295_CR14","doi-asserted-by":"publisher","unstructured":"Kiguchi N, Ko M-C. Chapter Ten\u2014Potential therapeutic targets for the treatment of opioid abuse and pain. In J.-X. Li (Ed.), Adv Pharmacol.\u00a02022;93:335\u2013371. Academic Press. https:\/\/doi.org\/10.1016\/bs.apha.2021.09.002.","DOI":"10.1016\/bs.apha.2021.09.002"},{"issue":"4","key":"1295_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/cts.13215","volume":"15","author":"HJ Hijma","year":"2022","unstructured":"Hijma HJ, van Brummelen EMJ, Siebenga PS, Groeneveld GJ. A phase I, randomized, double-blind, placebo-controlled, single- and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX-128, a highly selective Nav1.8 inhibitor, in healthy adults. Clin Transl Sci. 2022;15(4):981\u201393. https:\/\/doi.org\/10.1111\/cts.13215.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"1295_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2209870","volume":"389","author":"J Jones","year":"2023","unstructured":"Jones J, Correll DJ, Lechner SM, Jazic I, Miao X, Shaw D, Simard C, Osteen JD, Hare B, Beaton A, Bertoch T, Buvanendran A, Habib AS, Pizzi LJ, Pollak RA, Weiner SG, Bozic C, Negulescu P, White PF. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain. N Engl J Med. 2023;389(5):393\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2209870. This paper detailed the most recent phase 2 clinical trials of VX-458 and its efficacy in different doses and in comparison to placebo in post-surgical patients.","journal-title":"N Engl J Med"},{"issue":"2","key":"1295_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1152\/jn.2001.86.2.629","volume":"86","author":"M Renganathan","year":"2001","unstructured":"Renganathan M, Cummins TR, Waxman SG. Contribution of Nav1.8 Sodium Channels to Action Potential Electrogenesis in DRG Neurons. J Neurophysiol. 2001;86(2):629\u201340. https:\/\/doi.org\/10.1152\/jn.2001.86.2.629.","journal-title":"J Neurophysiol"},{"issue":"47","key":"1295_CR18","doi-asserted-by":"publisher","first-page":"19444","DOI":"10.1073\/pnas.1216080109","volume":"109","author":"CG Faber","year":"2012","unstructured":"Faber CG, Lauria G, Merkies ISJ, Cheng X, Han C, Ahn H-S, Persson A-K, Hoeijmakers JGJ, Gerrits MM, Pierro T, Lombardi R, Kapetis D, Dib-Hajj SD, Waxman SG. Gain-of-function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci. 2012;109(47):19444\u20139. https:\/\/doi.org\/10.1073\/pnas.1216080109.","journal-title":"Proc Natl Acad Sci"},{"key":"1295_CR19","doi-asserted-by":"publisher","first-page":"135844","DOI":"10.1016\/j.neulet.2021.135844","volume":"753","author":"Y Xue","year":"2021","unstructured":"Xue Y, Chidiac C, Herault Y, Gaveriaux-Ruff C. Pain behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) mutant rodent models. Neurosci Lett. 2021;753:135844. https:\/\/doi.org\/10.1016\/j.neulet.2021.135844. This paper detailed the underlying mechanisms behind the rational to pursue the development of pharmacologic NaV1.7 inhibitors for the treatment of pain, primarily assessing NaV1.7 gene knockout mice models.","journal-title":"Neurosci Lett"},{"key":"1295_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.933874","author":"H Tenza-Ferrer","year":"2022","unstructured":"Tenza-Ferrer H, Collodetti M, Nicolau EDS, Birbrair A, Magno LAV, Romano-Silva MA. Transiently Nav1.8-expressing neurons are capable of sensing noxious stimuli in the brain. Front Cell Neurosci. 2022. https:\/\/doi.org\/10.3389\/fncel.2022.933874.","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"1295_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1536\/ihj.52.146","volume":"J52","author":"P Facer","year":"2011","unstructured":"Facer P, Punjabi PP, Abrari A, Kaba RA, Severs NJ, Chambers J, Kooner JS, Anand P. Localisation of SCN10A Gene Product Nav1.8 and Novel Pain-Related Ion Channels in Human Heart. Inte Heart. 2011;J52(3):146\u201352. https:\/\/doi.org\/10.1536\/ihj.52.146.","journal-title":"Inte Heart"},{"issue":"6","key":"1295_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10557-019-06931-8","volume":"33","author":"KE Odening","year":"2019","unstructured":"Odening KE. The role of Nav1.8 in cardiac electrophysiology\u2014a matter of the heart or the nerve? Cardiovasc Drugs Ther. 2019;33(6):645\u20137. https:\/\/doi.org\/10.1007\/s10557-019-06931-8.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"13","key":"1295_CR23","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/cvr\/cvy152","volume":"114","author":"N Dybkova","year":"2018","unstructured":"Dybkova N, Ahmad S, Pabel S, Tirilomis P, Hartmann N, Fischer TH, Bengel P, Tirilomis T, Ljubojevic S, Renner A, Gummert J, Ellenberger D, Wagner S, Frey N, Maier LS, Streckfuss-B\u00f6meke K, Hasenfuss G, Sossalla S. Differential regulation of sodium channels as a novel proarrhythmic mechanism in the human failing heart. Cardiovasc Res. 2018;114(13):1728\u201337. https:\/\/doi.org\/10.1093\/cvr\/cvy152.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"1295_CR24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/ehf2.12378","volume":"6","author":"S Ahmad","year":"2019","unstructured":"Ahmad S, Tirilomis P, Pabel S, Dybkova N, Hartmann N, Molina CE, Tirilomis T, Kutschka I, Frey N, Maier LS, Hasenfuss G, Streckfuss-B\u00f6meke K, Sossalla S. The functional consequences of sodium channel NaV1.8 in human left ventricular hypertrophy. ESC Heart Fail. 2019;6(1):154\u201363. https:\/\/doi.org\/10.1002\/ehf2.12378.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"1295_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bja.2019.06.014","volume":"123","author":"H Hermanns","year":"2019","unstructured":"Hermanns H, Hollmann MW, Stevens MF, Lirk P, Brandenburger T, Piegeler T, Werdehausen R. Molecular mechanisms of action of systemic lidocaine in acute and chronic pain: A narrative review. Br J Anaesth. 2019;123(3):335\u201349. https:\/\/doi.org\/10.1016\/j.bja.2019.06.014.","journal-title":"Br J Anaesth"},{"issue":"4","key":"1295_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/j.1532-2149.2013.00400.x","volume":"18","author":"J Sawynok","year":"2014","unstructured":"Sawynok J. Topical analgesics for neuropathic pain: Preclinical exploration, clinical validation, future development. European Journal of Pain (London, England). 2014;18(4):465\u201381. https:\/\/doi.org\/10.1002\/j.1532-2149.2013.00400.x.","journal-title":"European Journal of Pain (London, England)"},{"issue":"1\u20132","key":"1295_CR27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/s0304-3959(01)00391-8","volume":"95","author":"J Lai","year":"2002","unstructured":"Lai J, Gold MS, Kim CS, Bian D, Ossipov MH, Hunter JC, Porreca F. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain. 2002;95(1\u20132):143\u201352. https:\/\/doi.org\/10.1016\/s0304-3959(01)00391-8.","journal-title":"Pain"},{"issue":"12","key":"1295_CR28","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1021\/acschemneuro.9b00547","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Cai S, Moutal A, Yu J, G\u00f3mez K, Madura CL, Shan Z, Pham NYN, Serafini MJ, Dorame A, Scott DD, Fran\u00e7ois-Moutal L, Perez-Miller S, Patek M, Khanna M, Khanna R. The natural flavonoid naringenin elicits analgesia through inhibition of NaV1.8 voltage-gated sodium channels. ACS Chem Neurosci. 2019;10(12):4834\u201346. https:\/\/doi.org\/10.1021\/acschemneuro.9b00547.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"1295_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40122-019-0114-4","volume":"8","author":"I Urits","year":"2019","unstructured":"Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O. An update of current cannabis-based pharmaceuticals in pain medicine. Pain Ther. 2019;8(1):41\u201351. https:\/\/doi.org\/10.1007\/s40122-019-0114-4.","journal-title":"Pain Ther"},{"issue":"30","key":"1295_CR30","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1523\/JNEUROSCI.3216-20.2021","volume":"41","author":"H-XB Zhang","year":"2021","unstructured":"Zhang H-XB, Bean BP. Cannabidiol inhibition of murine primary nociceptors: tight binding to slow inactivated states of Nav1.8 channels. J Neurosci: Official J Soc Neurosci. 2021;41(30):6371\u201387. https:\/\/doi.org\/10.1523\/JNEUROSCI.3216-20.2021.","journal-title":"J Neurosci: Official J Soc Neurosci"},{"issue":"12","key":"1295_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41582-020-00415-2","volume":"16","author":"M Alsaloum","year":"2020","unstructured":"Alsaloum M, Higerd GP, Effraim PR, Waxman SG. Status of peripheral sodium channel blockers for non-addictive pain treatment. Nat Rev Neurol. 2020;16(12):12. https:\/\/doi.org\/10.1038\/s41582-020-00415-2.","journal-title":"Nat Rev Neurol"},{"issue":"20","key":"1295_CR32","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1073\/pnas.0611364104","volume":"104","author":"MF Jarvis","year":"2007","unstructured":"Jarvis MF, Honore P, Shieh C-C, Chapman M, Joshi S, Zhang X-F, Kort M, Carroll W, Marron B, Atkinson R, Thomas J, Liu D, Krambis M, Liu Y, McGaraughty S, Chu K, Roeloffs R, Zhong C, Mikusa JP, ... Krafte DS. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci. 2007;104(20):8520\u20135. https:\/\/doi.org\/10.1073\/pnas.0611364104.","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"1295_CR33","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1093\/pm\/pnab032","volume":"22","author":"HJ Hijma","year":"2021","unstructured":"Hijma HJ, Siebenga PS, de Kam ML, Groeneveld GJ. A phase 1, randomized, double-blind, placebo-controlled, crossover study to evaluate the pharmacodynamic effects of VX-150, a Highly Selective NaV1.8 inhibitor, in healthy male adults. Pain Med (Malden, Mass). 2021;22(8):1814\u201326. https:\/\/doi.org\/10.1093\/pm\/pnab032.","journal-title":"Pain Med (Malden, Mass)"},{"key":"1295_CR34","doi-asserted-by":"publisher","first-page":"115371","DOI":"10.1016\/j.ejmech.2023.115371","volume":"254","author":"H Qin","year":"2023","unstructured":"Qin H, Wei A, Wang Y, Wang L, Xu H, Zhan Y, Tian X, Zheng Y, Gao Z, Hu Y. Discovery of selective NaV1.8 inhibitors based on 5-chloro-2-(4,4-difluoroazepan-1-yl)-6-methyl nicotinamide scaffold for the treatment of pain. Eur J Med Chem. 2023;254:115371. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115371.","journal-title":"Eur J Med Chem"},{"key":"1295_CR35","unstructured":"Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study. (2018, February 14). https:\/\/www.businesswire.com\/news\/home\/20180214005740\/en\/Vertex-Announces-Treatment-with-the-NaV1.8-Inhibitor-VX-150-Showed-Significant-Relief-of-Acute-Pain-in-Phase-2-Study."},{"key":"1295_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2021.100083","volume":"10","author":"HJ Hijma","year":"2021","unstructured":"Hijma HJ, Groeneveld GJ. Analgesic drug development: Proof-of-mechanism and proof-of-concept in early phase clinical studies. Med Drug Discov. 2021;10:100083. https:\/\/doi.org\/10.1016\/j.medidd.2021.100083.","journal-title":"Medicine in Drug Discovery"},{"key":"1295_CR37","doi-asserted-by":"publisher","first-page":"103267","DOI":"10.1016\/j.resp.2019.103267","volume":"270","author":"M Brozmanova","year":"2019","unstructured":"Brozmanova M, Svajdova S, Pavelkova N, Muroi Y, Undem BJ, Kollarik M. The voltage-gated sodium channel NaV1.8 blocker A-803467 inhibits cough in the guinea pig. Respir Physiol Neurobiol. 2019;270:103267. https:\/\/doi.org\/10.1016\/j.resp.2019.103267.","journal-title":"Respir Physiol Neurobiol"},{"issue":"4","key":"1295_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1124\/molpharm.122.000593","volume":"103","author":"S Jo","year":"2023","unstructured":"Jo S, Zhang H-XB, Bean BP. Use-dependent relief of inhibition of Nav1.8 channels by A-887826. Mol Pharmacol. 2023;103(4):221\u20139. https:\/\/doi.org\/10.1124\/molpharm.122.000593.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"1295_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bmc.2018.12.002","volume":"27","author":"AD Brown","year":"2019","unstructured":"Brown AD, Bagal SK, Blackwell P, Blakemore DC, Brown B, Bungay PJ, Corless M, Crawforth J, Fengas D, Fenwick DR, Gray V, Kemp M, Klute W, Malet Sanz L, Miller D, Murata Y, Payne CE, Skerratt S, Stevens EB, Warmus JS. The discovery and optimization of benzimidazoles as selective NaV1.8 blockers for the treatment of pain. Bioorg Med Chem. 2019;27(1):230\u20139. https:\/\/doi.org\/10.1016\/j.bmc.2018.12.002.","journal-title":"Bioorg Med Chem"},{"key":"1295_CR40","unstructured":"Drug Overdose Deaths | Drug Overdose | CDC Injury Center. (2023, August 22). https:\/\/www.cdc.gov\/drugoverdose\/deaths\/index.html."},{"issue":"5","key":"1295_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.13563","volume":"6","author":"RL Nahin","year":"2023","unstructured":"Nahin RL, Feinberg T, Kapos FP, Terman GW. Estimated rates of incident and persistent chronic pain among US adults, 2019\u20132020. JAMA Netw Open. 2023;6(5):e2313563. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.13563.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1295_CR42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.1532","volume":"2","author":"TJ Smith","year":"2019","unstructured":"Smith TJ, Hillner BE. The cost of pain. JAMA Netw Open. 2019;2(4):e191532. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.1532.","journal-title":"JAMA Netw Open"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-024-01295-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-024-01295-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-024-01295-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:04:36Z","timestamp":1728432276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-024-01295-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1295"],"URL":"https:\/\/doi.org\/10.1007\/s11916-024-01295-7","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"25 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"ADK is a section editor for CPHRs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article is based on previous studies and contains no new studies with human participants or animals performed by any authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}